Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Interactive Features

Quiz
Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma With Extrahepatic Metastases
11/27/2023
Do you know which outcome was less frequent among patients with cholangiocarcinoma with extrahepatic metastases who received liver-directed radiotherapy? Take our quick quiz to find out!
Do you know which outcome was less frequent among patients with cholangiocarcinoma with extrahepatic metastases who received liver-directed radiotherapy? Take our quick quiz to find out!
Do you know which outcome was...
11/27/2023
Oncology
Quiz
Real-World Experience With Gemcitabine-Cisplatin Plus Durvalumab For Biliary Tract Cancer
11/27/2023
Do you know the results of the real-world analysis of the efficacy of gemcitabine and cisplatin plus durvalumab among patients with advanced biliary tract cancer? Take our quick quiz to find out!
Do you know the results of the real-world analysis of the efficacy of gemcitabine and cisplatin plus durvalumab among patients with advanced biliary tract cancer? Take our quick quiz to find out!
Do you know the results of the...
11/27/2023
Oncology
Quiz
Dual IDH1/2 Inhibitor Response Rate in Cholangiocarcinoma
07/20/2023
What was the response rate among patients with locally advanced or metastatic IDH1/2 mutant cholangiocarcina who received the dual IDH1/2 inhibitor LY3410738 in combination with cisplatin-gemcitabine?
What was the response rate among patients with locally advanced or metastatic IDH1/2 mutant cholangiocarcina who received the dual IDH1/2 inhibitor LY3410738 in combination with cisplatin-gemcitabine?
What was the response rate among...
07/20/2023
Oncology

Advertisement

Quiz
Adjuvant or Neoadjuvant Chemotherapy for Non-Metastatic Cholangiocarcinoma
06/15/2023
True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.
True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.
True or False: Patients with...
06/15/2023
Oncology
Quiz
Adjuvant or Neoadjuvant Chemotherapy for Non-Metastatic Cholangiocarcinoma
06/15/2023
True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.
True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.
True or False: Patients with...
06/15/2023
Oncology
Quiz
Cholangioscopy for Diagnosis of Cholangiocarcinoma
06/15/2023
When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.
When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.
When used to diagnose...
06/15/2023
Oncology

Advertisement

Quiz
Cholangioscopy for Diagnosis of Cholangiocarcinoma
06/15/2023
When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.
When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.
When used to diagnose...
06/15/2023
Oncology
Quiz
Incidence of IDH Mutations in Cholangiocarcinoma
05/09/2023
In what percentage of patients with cholangiocarcinoma does an IDH mutation occur?
In what percentage of patients with cholangiocarcinoma does an IDH mutation occur?
In what percentage of patients...
05/09/2023
Oncology
Quiz
Incidence of IDH Mutations in Cholangiocarcinoma
05/09/2023
In what percentage of patients with cholangiocarcinoma does an IDH mutation occur?
In what percentage of patients with cholangiocarcinoma does an IDH mutation occur?
In what percentage of patients...
05/09/2023
Oncology

Advertisement

Quiz
Quiz: IDH Mutations in Biliary Tract Cancers
04/11/2023
Which type of biliary tract cancer is more likely to be IDH-mutant?
Which type of biliary tract cancer is more likely to be IDH-mutant?
Which type of biliary tract...
04/11/2023
Oncology

Advertisement

Advertisement

Advertisement

Recent News

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use